Remove 2023 Remove Clinical Research Remove Drug Development Remove Pharma Companies
article thumbnail

What will the 2023 drug discovery landscape look like?

Drug Discovery World

DDW Multimedia Editor Megan Thomas observes the 2023 drug discovery landscape, speaking to industry experts and looking at the foundations of 2022 on which next year will lean. Virtual clinical trials ‘Virtual’ and ‘technology’ are concepts which are readily exchanged in this industry, but these are more than just buzzwords.

article thumbnail

Why Do Pharma Companies Outsource to CROs?

Vial

Sponsors often contract a CRO to delegate specific day-to-day tasks, streamlining their research processes and enhancing efficiency. Conclusion As the global clinical trials outsourcing market continues to expand, CROs are increasingly recognized as essential partners in the drug development ecosystem.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Survey Sheds Light on Current Trends & Opportunities in Site and Patient Recruitment

PPD

Their services help engage a suitable participant pool, facilitate clinical trial participation, ensure that selected sites have the resources to support clinical trial activities and more. Patient education programs and resources can help inform potential participants of the critical role they can play in clinical research.

article thumbnail

What is the largest CRO in the US?

Vial

Introduction Contract research organizations (CROs) are essential in pharmaceutical research and development (R&D). By geographical region, the global CRO services market in 2023 was dominated by North America. billion in 2023 attributable to its laboratory products and biopharma services segment (53.8%

article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

From the Beatson Institute for Cancer Research in Glasgow, to Edinburgh Drug Discovery in the University of Edinburgh’s Institute for Genetics and Cancer (IGC). At ELRIG’s Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provided a snapshot of drug discovery in Scotland.

Drugs 189